Home › Compare › OTPMF vs ABBV
OTPMF yields 45.25% · ABBV yields 3.06%● Live data
📍 OTPMF pulled ahead of the other in Year 1
Combined, OTPMF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of OTPMF + ABBV for your $10,000?
OPTiM Corporation provides various internet-based services in Japan. It offers AI services, including OPTiM artificial intelligence (AI) Camera, an image analysis service and OPTiM Physical Security; Internet of Things (IoT) services, such as OPTiM Cloud IoT OS and OPTiM Store, a platform to create business app marketplace; and robotics/hardware services. The company also provides other services comprising Optimal Biz, which allows an IT administrator to manage IT devices in an office; Optimal Remote, a support tool to provide support and reduce diagnostic time, as well as a maintenance tool to control terminals located in distant places; Optimal Second Sight, a solution for live video to be shared through a smart glass, smartphone, or tablet; and OPTiM Café, a service that allows screen sharing without adapter for devices. In addition, it offers support services, which include Optimal Diagnosis and Repair, a tool to find and repair troubles on smartphones, tablets, PCs, and routers on the network; and Optimal Setup to automatically setup routers that are available for telecommunication carriers, as well as Optimal Guard to prevent spoofing and information leakage by detecting, stopping, and deleting malicious executable files. The company was incorporated in 2000 and is headquartered in Tokyo, Japan.
Full OTPMF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.